İmmünoglobulin tedavisi

İmmünglobulin tedavisinin koruyucu etkisi son 50 yıldan beri bilinmektedir. İmmünglobulin, IgG içeren steril bir ürün olup adale içine, cilt altına ve intravenöz uygulanabilen preparatları bulunur. Intravenöz immünglobulin (IVIG)’in, diğer immünglobulinlere göre bazı üstünlükleri vardır. Immün globulin preparatları güvenli ve etkilidir. İnsan immünglobulin tedavisinin, X-e bağlı agammaglobulinemi (X-LA), değişken immün yetersizlik (CVI), hiper-IgM sendromu ve kombine B- ve T-hücre eksikliği gibi antikor eksikliği olan hastalar için temel tedavi yöntemidir.Bu yazıda konuya ilişkin en sık sorulan sorulara yanıtlar verilecek ve IVIG tedavisindeki güncel bilgiler aktarılacaktır.

Immunoglobulin therapy

The protective effect of immunoglobulin administration has been known for the last 50 years. Immune globulin (IG)is a sterile IgG product, prepared for intramuscular, subcutaeous injection and intravenous infusion. Intravenous immunoglobulin (IVIG) has several advantages over other immunoglobulins. Immunoglobulin preparations are safe and effective. Human immunoglobulin replacement therapy is the mainstay of therapy for the patients with antibody deficiencies such as X-linked agammaglobulinemia (X-LA), common variable immunodeficiencies (CVI), hyper-IgM syndrome and combined B- and T-cell defect.In this review, you will find the answers to commonly asked questions related to IVIG and recent advances in IVIG therapy.

Kaynakça

1. Stiehm ER, Ochs HD, Winkelstein J. Immundeficiency Disorders; General Considereation. In Ochs, HD, Stiehm ER,Winkelstein J(eds) Immunologic Disorders in infant and children. 5th edition Elsevier Saunders Company, Pennsylvania 2004: 332-40.

2. Stiehm ER. Conventional therapy of primary immunodeficiency diseases. In Ochs HD, Smith CIE, Puck.JM(eds). Primary immundeficiency diseases; a molecularand genetic approach. New York, Oxford University press, 1999; 448-58.

3. Cunningham-Rundles C. Intravenous immune serum globulin in immunodeficiency. Vox Sang 1985;49 Suppl 1:8-14.

4. Schwartz . S.A. Intravenous Immunglobulin treatment of immune deficiency disorders. Pediatr.Clin North Am 2000; 47(6); 1355-69.

5. Amman AJ, Stiehm ER: Antibody(B-cell) immunodeficiency disorders. In Stites DP, Terr AI, Parslow TG(eds). Medical Immunology.9th edition. Appeleton-Lange; 1996.p.332-44.

6. Stiehm ER. Vaerman JP, Fudenberg HH. Plasma infusions in immunologic deficiency states:metabolic and therapeutic studies. Blood 1966; 28: 918-38.

7. Medical research Council Working Party. Hypogammaglobulinemia in the United Kingdom.Lancet 1969; 1: 163-9.

8. Thampakkul S, Ballow M. Replacement intravenous immune serum immunoglobulin therapy in patients with antibody immune deficiency. Immunol Allergy Clin North America 2001; 21(1): 165-84.

9. Gardulf A, Hammarström L, Smith CIE. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338: 162-6.

10. Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher KET, Groncy PM, Kobayashi RH, Oleske JM, Roberts RL, Sandbert ET, Wakim ME. Slow subcutaneous human intraveneus imminoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J. Allergy Clin Immunol 1998; 101: 848-9.

11. Fontan G, Garcia MC, Pascual-Salcedo D, Lopez Trascasa M, Alvarez Doforno R, Ferreira A. Newindications for gamma globulins. An Esp Pediatr 1992; 36; 48: 135-8.

12. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990; 15; 112(12): 967-71.

13. Ibanez C, Sune P, Fierro A, Rodriguez S, Lopez M, Alvarez A, De Gracia J, Montoro JB. Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia. BioDrugs 2005; 19(1): 59-65.

14. Pautard B, Hachulla E, Bagotd'Arc M, Chantreuil L. Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children. Rev Med Interne 2003; 24(8): 505-13.

15. Ochs HD, Pinciaro PJ; Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24(3): 309-14.

16. Busse PJ, Razvi S, Cunningham-Rundles C Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109(6): 1001-4.

17. Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) andIGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3(9): 1325-33.

18. Berger M. Immunodeficiency Disorders. Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin N Am 2008: 28(2); 413-37.

19. Lee ML, Gale RP, Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Annu Rev Med 1997; 48: 93-102.

20. Abe T, Kawasugi K.Use of intravenous immunoglobulin in various medical conditions. A Japanese experience. Cancer 1991 Sep 15; 68(6 Suppl): 1454-9.

21. Imbach P. Intravenous immünoglobulin therapy for idiopathic thrombocytopenie purpura and other immun related disorders review and update of our experiences. Pediatr Infect Dis J 1998; 7(5); 120-6.

Kaynak Göster